Skip to main content
ABVC BIOPHARMA, INC. logo

ABVC BIOPHARMA, INC. — Investor Relations & Filings

Ticker · ABVC ISIN · US00091F1066 US Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2023-06-07 Regulatory Filings
Country US United States of America
Listing US ABVC

About ABVC BIOPHARMA, INC.

https://abvcpharma.com/

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes drugs and medical devices to address unmet medical needs. The company focuses on advancing a pipeline of botanical, plant-based pharmaceuticals and medical technologies sourced from research institutions. Its therapeutic areas of focus include oncology, ophthalmology, and central nervous system disorders such as major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD). Key products in development include Vitargus®, a biodegradable vitreous substitute for eye surgery, and botanical drug candidates for MDD and ADHD. Additionally, its subsidiary, BioKey, Inc., offers contract development and manufacturing services for nutritional and pharmaceutical products.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2023
Regulatory Filings Classification · 100% confidence The document is a letter from ABVC BioPharma, Inc. to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-1. It references a filing related to securities registration and does not contain financial statements or detailed financial data. The document is short (884 characters) and is a formal regulatory communication about a filing process, not a financial report or presentation. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2023-06-07 English
AMENDMENT NO. 3 TO FORM S-1
Regulatory Filings Classification · 100% confidence The document is a Pre-Effective Amendment No. 3 to a Registration Statement on Form S-1 filed with the SEC. It includes exhibits, consents, and legal opinions related to the registration of securities under the Securities Act of 1933. The document is not a financial report like an Annual Report (10-K) or Interim Report (IR), nor is it an earnings release or management discussion. It is a regulatory filing related to securities registration and amendments to that registration. The document length is 15,000 characters, and it contains detailed legal and procedural information about the registration statement, not financial statements or earnings data. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-06-07 English
AMENDMENT NO. 2 TO FORM S-1
Capital/Financing Update Classification · 100% confidence The document is a "Pre-Effective Amendment No. 2 to Form S-1 Registration Statement" filed with the SEC by ABVC BioPharma, Inc. It is a registration statement under the Securities Act of 1933, used for registering securities for public offering. The text includes a preliminary prospectus, details about the offering, selling stockholders, risk factors, management discussion and analysis, business description, executive compensation, and other typical sections of a registration statement. This is not an annual report, earnings release, or any other financial report but a capital raising filing. The Form S-1 and amendments thereto are filings related to capital/financing activities, specifically securities registration for public offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full registration statement amendment, not just an announcement or notice, so it is not RPA or RNS. Confidence is high given the clear identification of the form and content.
2023-06-01 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC Division of Corporation Finance regarding an Amendment No. 1 to a Registration Statement on Form S-1. It discusses responses to SEC staff comments and references filing amendments to the registration statement. The document is a correspondence related to a regulatory filing process, specifically about a registration statement amendment, and does not contain financial statements or detailed financial data. It is not a report itself but a regulatory communication. Given the short length (2211 characters) and the nature of the content, this fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and correspondence that do not fit other categories.
2023-06-01 English
PRELIMINARY PROXY STATEMENT
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Preliminary Proxy Statement filed on Schedule 14A with the SEC, as indicated by the header and the text. It is related to a special meeting of shareholders to vote on a reverse stock split proposal. The document includes detailed information about the meeting, voting procedures, and proxy solicitation. Proxy statements are materials sent to shareholders to provide information and request votes for meetings. This matches the definition of Proxy Solicitation & Information Statement (PSI). The document is not an announcement of a report, nor is it a full financial report or other filing type. Therefore, the correct classification is PSI with high confidence.
2023-05-31 English
CURRENT REPORT
Regulatory Filings
2023-05-26 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.